Efficacy of @entity4546 on cough, pulmonary function and quality of life of XXXX with @entity599 mustard lung injury: A placebo-control, cross-over clinical trial study.

@entity1 @entity5745 @entity354 @entity599 @entity4546 @entity130
BACKGROUND: @entity354 ( @entity354 ) is prevalent and related to more severe disease in @entity1 with respiratory problems. We evaluated the effects of antireflux therapy in warfare victims of exposure to @entity5745 with chronic cough. MATERIALS AND METHODS: This randomized, double-blind, placebo-controlled, cross-over study was conducted on 45 cases of @entity599 @entity130 with chronic cough (>= 8 weeks) and @entity354 . @entity1 were randomized into two groups, receiving either 20 mg twice daily @entity4546 -placebo (OP) or matching placebo (placebo- @entity4546 [PO]) for 4 months, followed by a 1-month washout period and the alternative treatment for 4 months. Assessments included @entity354 and cough, quality of life, and pulmonary function using spirometry. Leicester Cough Questionnaire and SF-36 were used for measuring quality of life. RESULTS: @entity1 in the OP group experienced a more decrease than those in the PO group in severity of Leicester cough scores during the first 4-month of trial. After crossing the groups, the OP group experienced an increase (P = 0.036) and the PO group experienced a nonsignificant decrease (P = 0.104) in the severity of scores. The OP group also experienced improvement in @entity354 symptoms and quality of life at the end of the trial, but changes in the PO group was not significant. There was no significant change in respiratory function indices in any groups. CONCLUSION: Long-term treatment with high-dose @entity4546 improved @entity354 as well as cough, and quality of life, but not changed respiratory function indices in @entity599 mustard injured cases with respiratory symptoms.
